HLS Therapeutics (OTCMKTS:HLTRF) Stock Price Down 12.5% – Here’s Why

Shares of HLS Therapeutics Inc. (OTCMKTS:HLTRF) fell 12.5% during mid-day trading on Tuesday . The stock traded as low as $3.00 and last traded at $3.00. 5,000 shares traded hands during trading, an increase of 323% from the average session volume of 1,181 shares. The stock had previously closed at $3.43.

HLS Therapeutics Price Performance

The business’s fifty day simple moving average is $3.35 and its 200 day simple moving average is $3.57.

About HLS Therapeutics

HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.

The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.